Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mondamine DH-1N is a medicated mouthwash developed by Earth Chemical Co. (Earth Corporation) for the management and suppression of dentin hypersensitivity. It is designed to alleviate the sharp, transient pain arising from exposed dentin in response to external stimuli such as cold air, cold water, and mechanical abrasion. The product is part of the Mondamine brand of oral care solutions and has been evaluated in clinical trials to assess its efficacy in reducing pain scores on an 11-point numerical rating scale (NRS). While the specific active ingredients of the DH-1N formulation are often proprietary in early clinical stages, products in the Mondamine sensitivity line typically utilize agents like potassium nitrate to desensitize dental nerves or aluminum lactate to occlude dentinal tubules, thereby preventing the hydrodynamic movement of fluid that triggers pain receptors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mondamine DH-1N.